Jump to contents

Researcher Information

last modified:2020/03/26

Professor OGAWA Kazuma

Laboratory Website

Faculty, Affiliation

Institute for Frontier Science Initiative

College and School Educational Field


Laboratory

Cinical and Analytical Sciences TEL:076-234-4460 FAX:076-234-4459

Academic Background

【Academic background(Doctoral/Master's Degree)】
Kyoto University Master Graduate School, Division of Pharmaceutical Sciences 200003 Completed
Kyoto University Doctor Graduate School, Division of Pharmaceutical Sciences 200205 Unfinished course
【Academic background(Bachelor's Degree)】
Kyoto University 199803
【Degree】
Doctor of Pharmaceutical Sciences

Career

(2002/06/01-2004/01/31)
Kanazawa University Advanced Science Research Center(2004/02/01-2007/03/31)
Kanazawa University Advanced research center(2007/04/01-2009/03/31)
Kanazawa University(2009/04/01-)

Year & Month of Birth

Academic Society





The Japanese Cancer Association



Award

○The Third Best Paper Award for Young Researcher (The Japanese Society of Nuclear Medicine)(2006)
○The Pharmaceutical Society of Japan Award for Divisional Scientific Promotion(2019)

Specialities

Radiation science、Laboratory medicine、Physical pharmacy

Speciality Keywords

Radiopharmaceutical,Cancer,Bone

Research Themes

the development of radiopharmaceuticals

Books

Papers

  •  Design of radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS 47 10 753-761 2004/10
  •  A Tc-99m-labeled long chain fatty acid derivative for myocardial imaging BIOCONJUGATE CHEMISTRY 15 2 389-393 2004/03
  •  Control of radioactivity pharmacokinetics of 99mTc-HYNIC-labeled polypeptides derivatized with ternary ligand complexes BIOCONJUGATE CHEMISTRY 13 3 491-501 2002/05
  •  Synthesis and evaluation of a monoreactive DOTA derivative for indium-111-based residualizing label to estimate protein pharmacokinetics JOURNAL OF PHARMACY AND PHARMACOLOGY 54 8 1073-1081 2002/08
  •  Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides NUCLEAR MEDICINE AND BIOLOGY 28 7 761-768 2001/07

show all

  •  Significance of 111In-DTPA chelate in renal radioactivity levels of 111In-DTPA-conjugated peptides NUCLEAR MEDICINE AND BIOLOGY 28 4 459-468 2001/04
  •  99mTc-HYNIC-derivatized ternary ligand complexes for 99mTc-labeled polypeptides with low in vivo protein binding NUCLEAR MEDICINE AND BIOLOGY 28 3 215-224 2001/03
  •  Renal metabolism of 3-iodohippuryl N-maleoyl-L-lysine (HML)-conjugated Fab fragments BIOCONJUGATE CHEMISTRY 12 2 178-185 2001/03
  •  Plasma protein binding of 99mTc-labeled hydrazino nicotinamide derivatized polypeptides and peptides NUCLEAR MEDICINE AND BIOLOGY 28 2 155-164 2001/02
  •  Technetium-99m-labeled medium-chain fatty acid analogues metabolized by b-oxidation: radiopharmaceutical for assessing liver function BIOCONJUGATE CHEMISTRY 10 3 386-394 1999/05
  •  Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins BIOCONJUGATE CHEMISTRY 10 3 1999 1999/05
  •  The integrity of the disulfide bond in a cyclic somatostatin analog during 99mTc complexation reactions NUCLEAR MEDICINE AND BIOLOGY 26 8 883-890 1999/08
  •  Species difference in radioactivity elimination from liver parenchymal cells after injection of radiolabeled proteins NUCLEAR MEDICINE AND BIOLOGY 26 3 281-289 1999/03
  •  Development of a rhenium-186-labeled MAG3 conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. K. Ogawa, T. Mukai, Y. Arano, M. Ono, H. Hanaoka, S. Ishino, K. Hashimoto, H. Nishimura, and H. Saji BIOCONJUGATE CHEMISTRY 16 4 751-757 2005/07
  •  Rhenium-186-monoaminemonoamidedithiols conjugated bisphosphonate derivatives for bone pain palliation. K. Ogawa, T. Mukai, Y. Arano, A. Otaka, M. Ueda, T. Uehara, Y. Magata, K. Hashimoto, and H. Saji NUCLEAR MEDICINE AND BIOLOGY 33 4 513-520 2006/05
  •  Development of a novel technetium-99m-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. K. Ogawa, T. Mukai, Y. Inoue, M. Ono, and H. Saji JOURNAL OF NUCLEAR MEDICINE 47 12 2042-2047 2006/12
  •  Therapeutic effects for the palliation of metastatic bone pain of a rhenium-186 complex-conjugated bisphosphonate in an animal model. K. Ogawa, T. Mukai, D. Asano, H. Kawashima, S. Kinuya, K. Shiba, K. Hashimoto, H. Mori, and H. Saji JOURNAL OF NUCLEAR MEDICINE 48 1 122-127 2007/01
  •  Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases K. Ogawa, T. Mukai, K. Kawai, N. Takamura, H. Hanaoka, K. Hashimoto, K. Shiba, H. Mori, and H. Saji EUROPEAN JOURNAL OF NUCLEAR MEDICINE 36 1 115-121 2009/01
  •  Development of 90Y-DOTA conjugated bisphosphonate for treatment of painful bone metastases. K. Ogawa, H. Kawashima, K. Shiba, K. Washiyama, M. Yoshimoto, Y. Kiyono, M. Ueda, H. Mori, and H. Saji NUCLEAR MEDICINE AND BIOLOGY 36 2 129-135 2009/02
  •  Postconditioning Accelerates Myocardial Inflammatory Resolution Demonstrated by 14C-methionine Imaging and Attenuates Ventricular Remodeling after Ischemia and Reperfusion. J. Taki, A. Inaki, H. Wakabayashi, I. Matsunari, K. Imanaka-Yoshida, K. Ogawa, M. Hiroe, K. Shiba, S. Kinuya.  Circulation Journal 83 2520-2526 2019
  •  L-type amino acid transporter LAT1 regulates osteoclastogenesis and bone homeostasis through the mTORC1 pathway. K. Ozaki, T. Yamada, T. Horie, A. Ishizaki, M. Hiraiwa, T. Iezaki, G. Park, K. Fukasawa, H. Kamada, K. Tokumura, M. Motono, K. Kaneda, K. Ogawa, H. Ochi, S. Sato, Y. Kobayashi, Y. Shi, P.M. Taylor, E. Hinoi. Science Signaling 12 eaaw3921 2019
  •  20S Proteasome Inhibitory Activity of [N-(9-Anthracenylmethyl)-1,3-propanediamine] (2,2’-Bipyridine) Palladium(II) Chloride. T. Kiwada, H. Takayama. H. Katakasu, K. Ogawa, A. Odani. Chem Lett 48 936-938 2019
  •  New coordination compounds of citric acid and polyamines with lanthanide ions - potential application in monitoring the treatment of cancer diseases. M. Zabiszaka, M. Nowaka, M. Gabryela, K. Ogawa, M. Kaczmareka, Z. Hnatejkoa, R. Jastrzab.  J Inorg Biochem 198 110715 2019
  •  Development of diagnostic and therapeutic probes with controlled pharmacokinetics for use in radiotheranostics. K. Ogawa Chem Pharm Bull 67 897-903 2019
  •   Syntheses and evaluation of a homologous series of aza-vesamicol as improved radioiodine-labeled probes for sigma-1 ireceptor imaging.  K. Ogawa, R. Masuda, K. Mishiro, M. Wang, T. Kozaka, K. Shiba, S. Kinuya, A. Odani. Bioorg Med Chem 27 1990-1996 2019
  •  A platinum functional porphyrin conjugate: an excellent cancer killer for photodynamic therapy. X. Hu, K. Ogawa, S. Li, T Kiwada, A. Odani.  Bull Chme Soc Jap 92 790-796 2019
  •   Development of radiolabeled bis(zinc(II)-dipicolylamine) complexes for cell death imaging.  M. Aoki, A. Odani, K. Ogawa. Ann Nucl Med 33 317-325 2019
  •  Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.  A. Ishizaki, K. Mishiro, K. Shiba, H. Hanaoka, S. Kinuya, A. Odani, K. Ogawa. Ann Nucl Med 33 4 244-251 2019
  •  Radiotheranostics with radiolanthanides: designs, development strategies, and medical applications.  K. Mishiro, H. Hanaoka, A. Yamaguchi, K. Ogawa. Coordination Chemistry Reviews 383 104-131 2019
  •  The Potential of The Vesicular Acetylcholine Transporter (VAChT) Imaging Using Radiolabeled o-Bromo-trans-decalinvesamicol (OBDV) as a New PET Ligand. M.A. Azim, T. Kozaka, I. Uno, D. Miwa, Y. Kitamura, K. Ogawa, A. Makino, Y. Kiyono, K. Shiba Synapse 68 10 445-453 2014
  •  Effect of postconditioning on dynamic expression of tenascin-C and left ventricular remodeling after myocardial ischemia and reperfusion.  J. Taki, A. Inaki, H. Wakabayashi, I. Matsunari, K. Imanaka-Yoshida, K. Ogawa, M. Hiroe, K. Shiba, T. Yoshida, S. Kinuya EJNMMI Research 5 2015
  •  Design, synthesis, and biological evaluation of radioiodinated benzo[d]imidazole-quinoline derivatives for platelet-derived growth factor receptor β (PDGFRβ) imaging. N. Effendi, K. Mishiro, T. Takarada, A. Makino, D. Yamada, Y. Kitamura, K. Shiba, Y. Kiyono, A. Odani, K. Ogawa Bioorg Med Chem 27 383-393 2019
  •  Hollow submicron spheres fabricated from cyanoacrylate instant adhesive Makuta, Toshinori; Yoshihiro, Yuki; Sutoh, Taichi; Ogawa, Kazuma Materials Letters 131 310-312 2014/09/15 
  •  Development of radiopharmaceuticals for diagnosis and therapy of metastatic bone cancer Ogawa, Kazuma Yakugaku Zasshi 132 10 1151-1157 2012/10/30 
  •  Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases. K. Ogawa, A. Ishizaki Biomed Res Int 2015
  •  Radiogallium complex-conjugated bifunctional peptides for detecting primary cancer and bone metastases simultaneously. K. Ogawa, J. Yu, A. Ishizaki, M. Yokokawa, M. Kitamura, Y. Kitamura, K. Shiba, A. Odani Bioconjug Chem 26 8 1561-1570 2015
  •  Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy. K. Ogawa, Y. Mizuno, K. Washiyama, K. Shiba, N. Takahashi, T. Kozaka, S. Watanabe, A. Shinohara,A. Odani Nucl Med Biol 42 11 875-879 2015
  •  Development of Radiopharmaceuticals for Diagnosis and Therapy of Metastatic Bone Cancer Ogawa, Kazuma YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 132 10 1151-1157 2012
  •  Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT Yeh, Hsin Hsien;Ogawa, Kazuma;Balatoni, Julius;Mukhapadhyay, Uday;Pal, Asutosh;Gonzalez-Lepera, Carlos;Shavrin, Aleksandr;Soghomonyan, Suren;Flores, Leo, II;Young, Daniel;Volgin, Andrei Y.;Najjar, Amer M.;Krasnykh, Victor;Tong, William;Alauddin, Mian M.;Gelovani, Juri G. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 108 4 1603-1608 2011
  •  Radiolabeled apoptosis imaging agents for early detection of response to therapy Ogawa, Kazuma; Aoki, Miho Scientific World Journal 2014 2014/01/01 
  •  Radiotheranostics coupled between an At-211 labeled RGD peptide and a corresponding radioiodine labeled RGD peptide. K. Ogawa, T. Takeda, K. Mishiro, A. Toyoshima, K. Shiba, T. Yoshimura, A. Shinohara, S. Kinuya, A. Odani ACS Omega 4 4584-4591 2019
  •  Development of a novel radiobromine-labeled sigma-1 receptor imaging probe. K. Ogawa, R. Masuda, Y. Mizuno, A. Makino, T. Kozaka, Y. Kitamura, Y. Kiyono, K. Shiba, A. Odani. Nucl Med Biol 61 28-35 2018
  •  Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes. N. Effendi, K. Mishiro, T. Takarada, D. Yamada, R. Nishii, K. Shiba, S. Kinuya, A. Odani, K. Ogawa Sci Rep 8 10369 2018
  •  In vivo imaging of altered histone deacetylases activity in chemotherapy-induced neurotoxicity using 6-([18F]fluoroacetamido)-1-hexanoicanilide PET. N. Fukumitsu, S. Yeh, L. Flores, U. Mukhopadhyay, D. Young, K. Ogawa, H. Jeong, W. Tong J. Gelovani. Contrast Media & Molecular Imaging 2018 Article ID 3612027 2018
  •  Comparison of radioiodine- or radiobromine-labeled RGD peptides between direct and indirect labeling methods. K. Ogawa, T. Takeda, M. Yokokawa, J. Yu, A. Makino, Y. Kiyono, K. Shiba, S. Kinuya, A. Odani. Chem Pharm Bull 66 6 651-659 2018
  •  Complexes of myo-inositol-hexakisphosphate (InsP6) with zinc or lanthanum to enhance excretion of radioactive strontium from the body. K. Ogawa, M. Aoki, S. Kadono, A. Odani. PLoS ONE 13 4 e0195067 2018

Conference Presentations

  • Chlorella as a decorporation agent to enhance the elimination of radioactive elements. (conference:The 6th International Conference on Food Factors)(2015)

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○「MMP-2を標的とした体内動態化学制御型の新規腫瘍核医学診断薬剤の開発」(2004-) 
○「新規アポトーシスイメージング剤による癌・虚血再灌流障害治療効果超早期診断法の確立」(2006-) 
○「新規放射性薬剤を用いた包括的転移性骨腫瘍診断治療法の確立を目指した研究」(2009-) 
○「革新的癌診断治療システムの開発研究-骨腫瘍診断治療からDDSへ」(2011-2012) 
○「癌の原発巣、造骨性・溶骨性骨転移の同時診断治療を可能とする放射性薬剤の開発研究」(2015-2017) 
○「放射性ハロゲンを用いた包括的癌診断・治療法(ラジオセラノスティクス)の確立」(2018-2020) 

Classes (Bachelors)

○Analytical Chemistry 1(2019)
○Clinical Chemistry(2019)
○Analytical Chemistry 2(2019)
○Inorganic Pharmaceutical Chemistry(2019)
○Analytical, Environmental and Physical Sciences(2019)
○Experiments in Analysis and Measurements 1(2019)
○Laboratory Rotation 3(2019)
○Analytical, Environmental and Physical Sciences(2018)
○Clinical Chemistry(2018)
○Analytical Chemistry 2(2018)
○Laboratory Rotation 3(2018)
○Experiments in Analysis and Measurements 1(2018)
○Inorganic Pharmaceutical Chemistry(2018)
○Presentation and Debate (Freshman Seminar II)(2017)
○Analytical Chemistry 2(2017)
○Analytical, Environmental and Physical Sciences(2017)
○Clinical Chemistry(2017)
○Experiments in Analysis and Measurements 1(2017)
○Inorganic Pharmaceutical Chemistry(2017)
○Analytical Chemistry 2(2016)
○Analytical, Environmental and Physical Sciences(2016)
○Inorganic Pharmaceutical Chemistry(2016)
○Clinical Chemistry(2016)
○Experiments in Analysis and Measurements 1(2016)

Classes (Graduate Schools)

○Advanced Course of Pharmachemistry(2019)
○Introduction to Pharmachemistry(2019)
○Advanced Course of Pharmachemistry(2018)
○Introduction to Pharmachemistry(2018)
○Bioinorganic Chemistry(2017)
○Quantum Organic Chemistry(2017)
○Advanced Seminar on Pharmachemistry(2017)
○Diagnostic Imaging from The Point of View of Pharmaceutical Science(2017)
○Introduction to Pharmachemistry(2017)
○Advanced Organic Chemistry III(2017)
○Advanced Course of Pharmachemistry(2017)
○Bio-Functional Analytical Science(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top